The Korean Journal of Gastroenterology :eISSN 2233-6869 / pISSN 1598-9992

 

Table. 4.

Efficacy of RFA for Malignant Hilar Biliary Obstruction

Study No. Technical success No. of RFA session (range) Stent Complication early/late Recurrent biliary obstruction Patency (days) Survival (days)
Inoue et al. (2020)71 41 39/41 (95.1) 39a SBS, SEMS 2.4/7.7 38.5 (15/39) 230 N/A
Bokemeyer et al. (2019)72 32 (21 hilar) 100 54a (1-2) Plastic 85.2%, SEMS 14.8% 10/54 (18.5) N/A N/A 342/221 (control; p=0.046)
Tal et al. (2014)73 12 100 19a (1-5) Plastic Late bleeding 3
Cholangitis 4
N/A N/A 6.4 m
Kim et al. (2019)74 11 100 4b (2-8) Plastic, SEMS Early; pancreatitis (1), fever only (5) 27.3 (3) 30-day stent patency (100%) 191
Schmidt et al. (2016)75 14 100 31a Plastic, SEMS 28 (4); cholangitis, liver abscess, sepsis Premature stent replacements (<3 m), 29 (4) N/A N/A

Values are presented the number/number (%).

RFA, radiofrequency ablation; SEMS, self-expandable metal stent; N/A, not available; SBS, stent-by-stent.

aHabibTM EndoHPB Biopolar Radiofrequency Catheter (Boston Scientific, Marlborough, USA; EMcision UK, London, United Kingdom);

bTemperature-controlled ID-RFA catheter (ELRA; STARmed, Goyang, Korea) and RF generator (VIVA Combo; STARmed).

Korean J Gastroenterol 2021;78:94~104 https://doi.org/10.4166/kjg.2021.111
© Korean J Gastroenterol